Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues
Royalty	$ 0	$ 0	$ 0	$ 2,112
Product	25,483	575	75,795	4,201
Total Revenues	25,483	575	75,795	6,313
Operating Expenses
Research and development	4,445,877	3,180,177	11,968,424	10,567,988
General and administrative	2,426,854	1,080,308	6,053,613	4,292,666
Sales and marketing	715,044	244,510	1,601,816	734,355
Total Operating Expenses	7,587,775	4,504,995	19,623,853	15,595,009
Operating Loss	(7,562,292)	(4,504,420)	(19,548,058)	(15,588,696)
Other Income (Expenses)
Grant income	419,271	0	810,803	98,870
Gain / ( Loss) on disposal of fixed assets	0	200,393	(26,167)	293,595
Interest income	290	2,801	2,503	48,956
Interest expense	(38,767)	(34,722)	(120,636)	(91,105)
Total Other Income	380,794	168,472	666,503	350,316
Net Loss	(7,181,498)	(4,335,948)	(18,881,555)	(15,238,380)
Net Loss attributable to Non-Controlling Interest	45,065	8,050	102,028	23,396
Net Loss attributable to VolitionRx Limited Stockholders	(7,136,433)	(4,327,898)	(18,779,527)	(15,214,984)
Other Comprehensive (Loss) / Income
Foreign currency translation adjustments	(20,875)	(573,397)	68,710	(273,791)
Net Comprehensive Loss	$ (7,202,373)	$ (4,909,345)	$ (18,812,845)	$ (15,512,171)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited	$ (0.13)	$ (0.09)	$ (0.36)	$ (0.34)
Weighted Average Shares Outstanding
- Basic and Diluted	53,166,781	47,027,011	52,355,681	44,148,793